Literature DB >> 12208487

Effects of various fibrates on serum alkaline phosphatase activity.

Emanuel Ganotakis, Vasilios Tsimihodimos, Eleni Bairaktari, Evagelos Rizos, Vasilios Athyros, Constantinos Seferiades, Moses Elisaf.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12208487     DOI： 10.1016/s0021-9150(02)00117-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN： 0021-9150            Impact factor:   5.162


× No keyword cloud information.
  4 in total

1.  Pretreatment with peroxysome proliferator-activated receptor alpha agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock.

Authors:  Eric Wiel; Gilles Lebuffe; Emmanuel Robin; Gaëlle Gasan; Delphine Corseaux; Benoît Tavernier; Brigitte Jude; Régis Bordet; Benoît Vallet
Journal:  Intensive Care Med       Date:  2005-08-16       Impact factor: 17.440

Review 2.  Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.

Authors:  Thomas Dayspring; Gregory Pokrywka
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

3.  Effect of fenofibrate in combination with urate lowering agents in patients with gout.

Authors:  You-Hyun Lee; Chan-Hee Lee; Jisoo Lee
Journal:  Korean J Intern Med       Date:  2006-06       Impact factor: 2.884

Review 4.  Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Int J Nanomedicine       Date:  2006
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.